BIBLIOGRAPHY


ORIGINAL BIOMEDICAL RESEARCH PAPERS

1. Jones EA. Number of spermatogonia after X-irradiation of the adult rat. International Journal of Radiation Biology 1960; 2: 157-170.

2. Jones EA, Craigie A, Tavill AS, Franglen G, Rosenoer VM. Protein metabolism in the intestinal stagnant loop syndrome. Gut 1968; 9: 466-469.

3. Smallwood RA, Jones EA, Craigie A, Raia S, Rosenoer VM. The delivery of newly synthesized albumin and fibrinogen to the plasma in dogs. Clinical Science 1968; 35: 35-42.

4 Jones EA, Craigie A, Tavill AS, Simon W, Rosenoer VM. Urea kinetics and the direct measurement of the synthetic rate of albumin utilizing [14C]-carbonate. Clinical Science 1968; 35: 553-564.

5. Kreel L, Jones EA, Tavill AS. A comparative study of arteriography and scintillation scanning in space-occupying lesions of the liver. British Journal of Radiology 1968; 41: 401-411.

6. Jones EA, Smallwood RA, Craigie A, Rosenoer VM. The enterohepatic circulation of urea nitrogen. Clinical Science 1969; 37: 825-836.

7. Cain GD, Mayer G, Jones EA. Augmentation of albumin but not fibrinogen synthesis by corticosteroids in patients with hepatocellular diseases. Journal of Clinical Investigation 1970; 49: 2198-2204.

8. Jones EA, Bloomer JR, Berlin NI. The measurement of the synthetic rate of bilirubin from hepatic hemes in patients with acute intermittent porphyria. Journal of Clinical Investigation 1971; 50: 2259-2265.

9. Jones EA, Cain GD, Dickinson G. Corticosteroid-induced changes in urea metabolism in patients with hepatocellular diseases. Gastroenterology 1972; 62: 612-617.

10. Jones EA, Shrager R, Bloomer JR, Berk PD, Howe RB, Berlin NI. Quantitative studies of the delivery of hepatic synthesized bilirubin in plasma utilizing delta-aminolevulinic acid-14C and bilirubin-3H in man. Journal of Clinical Investigation 1972; 51: 2450-2458. (Year Book of Medicine 1973: 497-499).

11. Jones EA, Waldmann TA. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. Journal of Clinical Investigation 1972; 51: 2916-2927.

12. Jones EA, Young WB, Morson BC, Dawson AM. A study of six patients with hypertrophy of the gastric mucosa with particular reference to albumin metabolism. Gut 1972; 13: 270-277.

13. Potter BJ, Trueman AM, Jones EA. Serum complement in chronic liver disease. Gut 1973; 14: 451-456.

14. Tavill AS, Wood EJ, Kreel L, Jones EA, Gregory M, Sherlock S. The Budd-Chiari syndrome: Correlation between hepatic scintigraphy and the clinical, radiological and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology 1975; 68: 509-518. (Year Book of Medicine, 1976: 488-490; Year Book of Radiology, 1976: 56-58).

15. Potter BJ, Elias E, Jones EA. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis. Journal of Laboratory and Clinical Medicine 1976; 88: 427-439.

16. Balfour AH, Jones EA. The binding of plasma proteins to human placental cell membranes. Clinical Science and Molecular Medicine 1977; 52: 383-394.

17. Owens D, Jones EA, Carson ER. Studies of the kinetics of unconjugated [14C]-bilirubin metabolism in normal subjects and patients with compensated cirrhosis. Clinical Science and Molecular Medicine 1977; 52: 555-570.

18. Vierling JM, Nelson DL, Strober W, Bundy BM, Jones EA. In vitro cell mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. Journal of Clinical Investigation 1977; 60: 1116-1128.

19. Vierling JM, Steer CJ, Bundy BM, Strober W, Jones EA, Hague NE, Nelson DL. Studies of complement receptors on cytotoxic effector cells in human peripheral blood. Cellular Immunology 1978; 35: 403-413.

20. Blitzer BL, Waggoner JG, Jones EA, Gralnick HR, Towne D, Butler J, Weise V, Kopin IJ, Walters I, Teychenne PF, Goodman GD, Berk PD. A model of fulminant hepatic failure in the rabbit. Gastroenterology 1978; 74: 664-671.

21. Balfour AH, Jones EA. Properties of receptors for IgG on human placental cell membranes. International Archives of Allergy and Applied Immunology 1978; 56:
435-442.

22. Vierling JM, Shrager R, Rumble W, Aamodt R, Berman M, Jones EA. Incorporation of radiocopper into ceruloplasmin in normal subjects and patients with primary biliary cirrhosis and Wilson's disease. Gastroenterology 1978; 74: 652-660.

23. Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO. The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochemical and Biophysical Research Communications 1978; 81: 1047-1053.

24. Jones EA, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha-1-antitrypsin. Clinical Science and Molecular Medicine 1978; 55: 139-148.

25. Steer CJ, Furbish FS, Barranger JA, Brady RO, Jones EA. The uptake of agalacto-glucocerebrosidase by rat hepatocytes and Kupffer cells. FEBS Letters 1978; 91: 202-205.

26. Vierling JM, Steer CJ, Hickman JW, James SP, Jones EA. Cell-mediated cytotoxicity of desialylated human lymphocytes induced by a mitogenic mammalian liver protein. Gastroenterology 1978; 75: 456-461.

27. Barranger JA, Pentchev PG, Furbish FS, Steer CJ, Jones EA, Brady RO. Studies of lysosomal function. I. Metabolism of some complex lipids by isolated hepatocytes and Kupffer cells. Biochemical and Biophysical Research Communications 1978; 83: 1055-1060.

28. Jaffe CJ, Vierling JM, Jones EA, Lawley TJ, Frank MM. Receptor specific clearance by the reticuloendothelial system in chronic liver disease. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. Journal of Clinical Investigation 1978; 62: 1069-1077.

29. Potter BJ, Elias E, Fayers PM, Jones EA. Profiles of serum complement in patients with hepatobiliary diseases. Digestion 1978; 18: 371-383.

30. Teychenne PF, Jones EA, Ishak KG, Calne DB. Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate, a dopaminergic ergot derivative. Gastroenterology 1979; 76: 575-583.

31. Karsh J, Vergalla J, Jones EA. Alpha-1-antitrypsin phenotypes in rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism 1979; 22:
111-113.

32. Berman MD, Alter HJ, Ishak KG, Purcell RH, Jones EA. The chronic sequelae of non-A, non-B hepatitis. Annals of Internal Medicine 1979; 91: 1-6.

33. Steer CJ, Kusiak JW, Brady RO, Jones EA. Selective hepatic uptake of human hexosaminidase A by a specific glycoprotein recognition system on sinusoidal cells. Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 2774-2778.

34. Berman MD, Rabin L, O'Donnell J, Gratwohl AA, Graw RJ Jr, Deisseroth AB, Jones EA. The liver in long-term survivors of marrow transplant - chronic graft versus host disease. Journal of Clinical Gastroenterology 1980; 2: 53-63.

35. James SP, Elson CO, Jones EA, Strober W. Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis. Gastroenterology 1980; 79: 242- 254.

36. Steer CJ, James SP, Vierling JM, Hosea SW, Jones EA. The selective hepatic uptake of desialylated peripheral blood mononuclear cells in rabbits. Gastroenterology 1980; 79: 917-923.

37. James SP, Elson CO, Waggoner JG, Jones EA, Strober W. Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis. Journal of Clinical Investigation 1980; 66: 1305-1310.

38. Karsh J, Moutsopoulos HM, Vergalla J, Jones EA. Protease inhibitor phenotypes and pulmonary disease in patients with Sjogren's syndrome. Respiration 1981; 41: 60-65.

39. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Annals of Internal Medicine 1981; 94: 744-748.

40. Schafer DF, Fowler JM, Jones EA. Colonic bacteria: A source of gamma-aminobutyric acid in blood. Proceedings of the Society for Experimental Biology and Medicine 1981; 167: 301-303.

41. Berk PD, Schafer DF, Baruch J, Kulshrestha VK, Jones EA. Sorbent biocompatibility is a function of species and parameter studied, and choice of anticoagulant. Artificial Organs 1981; 5 suppl: 542-546.

42. Summerfield JA, Vergalla J, Jones EA. Modulation of a glycoprotein recognition system on rat hepatic endothelial cells by glucose and diabetes mellitus. Journal of Clinical Investigation 1982; 69: 1337-1347.

43. Dusheiko GM, Hoofnagle JH, Cooksley WGE, James SP, Jones EA. Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. Journal of Clinical Investigation 1983; 71: 1104-1113.

44. Horowitz ME, Schafer DF, Molnar P, Jones EA, Blasberg RG, Patlak CS, Waggoner JG, Fenstermacher JD. Increased blood-brain transfer in a rabbit model of acute liver failure. Gastroenterology 1983; 84: 1003-1011.

45. Schafer DF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, Jones EA. Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. Journal of Laboratory and Clinical Medicine 1983; 102: 870-880.

46. Ferenci P, Schafer DF, Kleinberger G, Hoofnagle JH, Jones EA. Serum levels of gamma-aminobutyric acid-like activity in patients with acute and chronic hepatocellular diseases. Lancet 1983; ii: 811-814.

47. Ferenci P, Covell D, Schafer DF, Waggoner JG, Shrager R, Jones EA. Metabolism of the inhibitory neurotransmitter gamma-aminobutyric acid in a rabbit model of fulminant hepatic failure. Hepatology 1983; 3: 507-512.

48. Vergalla J, Jones EA, Kew M. Alpha-1-antitrypsin deficiency and hepatocellular carcinoma. Determination of Pi phenotypes using isoelectric focusing. South African Medical Journal 1983; 64: 950-951.

49. Ferenci P, Pappas SC, Munson PJ, Jones EA. Changes in glutamate receptors on synaptic membranes associated with hepatic encephalopathy or hyperammonemia in the rabbit. Hepatology 1984; 4: 25-29.

50. Ferenci P, Jacobs R, Pappas SC, Schafer DF, Jones EA. Enzymes of cerebral GABA metabolism and synaptosomal GABA uptake in acute liver failure in the rabbit. Evidence for decreased GABA-transaminase activity. Journal of Neurochemistry 1984; 42: 1487-1490.

51. Minuk GY, Vergalla J, Ferenci P, Jones EA. Identification of an acceptor system for gamma-aminobutyric acid on isolated rat hepatocytes. Hepatology 1984; 4: 180-185.

52. Ferenci P, Pappas SC, Munson PJ, Henson K, Jones EA. Changes in the status of neurotransmitter receptors in a rabbit model of hepatic encephalopathy. Hepatology 1984; 4: 186-191.

53. Schafer DF, Pappas SC, Brody LE, Jacobs R, Jones EA. Visual evoked potentials in a rabbit model of hepatic encephalopathy. I. Sequential changes and comparisons with drug-induced comas. Gastroenterology 1984; 86: 540-545.

54. Pappas SC, Ferenci P, Schafer DF, Jones EA. Visual evoked potentials in a rabbit model of hepatic encephalopathy. II. Comparison of hyperammonemic encephalopathy, postictal coma, and coma induced by synergistic neurotoxins. Gastroenterology 1984; 86: 546-551.

55. Ferenci P, Pappas SC, Jones EA. L-leucine prevents ammonia-induced changes in glutamate receptors in the brain and in visual evoked potentials in the rabbit. Journal of Parenteral and Enteral Nutrition 1984; 8: 700-704.

56. Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA. Vitamin E deficiency in adults with chronic liver disease. American Journal of Clinical Nutrition 1985; 41: 66-72.

57. Minuk GY, Angus M, Brickman CM, Lawley TJ, Frank MM, Hoofnagle JH, Jones EA. Abnormal clearance of immune complexes from the circulation of patients with primary sclerosing cholangitis. Gastroenterology 1985; 88: 166-170.

58. James SP, Jones EA, Hoofnagle JH, Strober W. Circulating activated B cells in primary biliary cirrhosis. Journal of Clinical Immunology 1985; 5: 254-260.

59. James SP, Jones EA. Abnormal natural killer cytotoxicity in primary biliary cirrhosis: Evidence for a functional deficiency of cytolytic effector cells. Gastroenterology 1985; 89: 165-171.

60. Covell DG, Ferenci P, Schafer DF, Jones EA. A nonlinear kinetic model of gamma-aminobutyric acid metabolism in a rabbit model of acute liver failure. Mathematical Biosciences 1985; 75: 121-138.

61. Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, Jones EA, Brewer HB Jr. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89: 1266-1278.

62. Minuk GY, Vergalla J, Hanson RG, Hoofnagle JH, Frank MM, Jones EA. Anti-complement receptor activity in the serum of patients with primary biliary cirrhosis. Gut 1986; 27: 324-328.

63. Ferenci P, Jones EA, Hanbauer I. Lack of evidence for impaired dopamine receptor function in experimental hepatic coma in the rabbit. Neuroscience Letters 1986; 65: 60–64.

64. Hansen RG, Hoofnagle JH, Cooksley WG, Jones EA. In vitro synthesis and immunoregulation of antibody to hepatitis B surface antigen in man. Journal of Gastroenterology and Hepatology 1986; 1: 305–316.

65. Jicha DL, Davis GL, Peters MG, Hoofnagle JH, Jones EA. Effects of recombinant leukocyte interferon treatment on endogenous interferon production in patients with chronic type-B hepatitis. Journal of Interferon Research 1986; 6: 13–20.

66. Meryn S, Bauman WA, Pappas SC, Ferenci P, Jones EA. Brain cholecystokinin and vasoactive intestinal polypeptide: immunoreactivity in rabbits with hepatic coma. Liver 1986; 6: 281–285.

67. Avigan MI, Adamson G, Hoofnagle JH, Jones EA. The in vitro production of antibodies to mitochondrial antigens by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Hepatology 1986; 6: 999–1004.

68. Jones DB, Mullen KD, Roessle M, Maynard T, Jones EA. Hepatic encephalopathy. Application of visual evoked responses to test hypotheses of its pathogenesis in rats. Journal of Hepatology 1987; 4: 118–126.

69. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complications of long–term interferon–alpha therapy. Archives of Internal Medicine 1987; 147: 1577–1580.

70. Jones DB, Rustgi V, Kornhauser DM, Woods A, Quinn R, Hoofnagle JH, Jones EA. The disposition of 6–deoxyacyclovir, a xanthine oxidase–activated prodrug of acyclovir, in the isolated perfused rat liver. Hepatology 1987; 7: 345–348.

71. Bassett ML, Mullen KD, Skolnick P, Jones EA. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA–benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987; 93: 1069-1077.

72. Ferenci P, Riederer P, Jellinger K, Schafer DF, Jones EA. Changes in cerebral receptors for gamma aminobutyric acid in patients with hepatic encephalopathy. Liver 1988; 8: 225–230.

73. Basile AS, Gammal SH, Mullen KD, Jones EA, Skolnick P. Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. Journal of Neuroscience 1988; 8: 2414-2421.

74. Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology 1989; 96: 479–486.

75. Dooley JS, Vergalla J, Hoofnagle JH, Zoon KC, Munson PJ, Jones EA. Specific binding of human alpha interferon to high affinity cell surface binding sites on peripheral blood mononuclear cells. Journal of Laboratory and Clinical Medicine 1989; 113: 623–631.

76. Rossle M, Dekert J, Jones EA. Autoradiographic analysis of GABA/benzodiazepine receptors in an animal model of acute hepatic encephalopathy. Hepatology 1989; 10: 143-147.

77. Basile AS, Gammal SH, Jones EA, Skolnick P. The GABAA receptor complex in an experimental model of hepatic encephalopathy: Evidence for elevated levels of an endogenous benzodiazepine receptor ligand. Journal of Neurochemistry 1989; 53: 1057-1063.

78. Roessle M, Mullen KD, Jones EA. Cortical benzodiazepine binding in a rabbit model of hepatic encephalopathy. The effect of Triton–X100 on receptor solubilization. Metabolic Brain Disease 1989; 4: 203–212.

79. Suou T, Civeira MP, Kanof ME, Moreno–Otero R, Jones EA, James SP. Defective immunoregulation in primary biliary cirrhosis: CD4+, Leu–8+ T cells have abnormal activation and suppressor function in vitro. Hepatology 1989; 10: 408–413.

80. Mullen KD, Martin JV, Mendelson WB, Kaminsky–Russ K, Jones EA. Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy. Metabolic Brain Disease 1989; 4: 253–260.

81. Basile AS, Ostrowski NL, Gammal SH, Jones EA, Skolnick P. The GABAA receptor complex in hepatic encephalopathy. Autoradiographic evidence for the presence of elevated levels of a benzodiazepine receptor ligand. Neuropsychopharmacology 1990; 3: 61–67.

82. Bassett ML, Mullen KD, Scholtz B, Fenstermacher JD, Jones EA. Increased brain uptake of GABA in a rabbit model of hepatic encephalopathy. Gastroenterology 1990; 98: 747–757.

83. Gammal SH, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 1990; 11: 371–378.

84. Basile AS, Pannell L, Jaouni T, Gammal SH, Fales HM, Jones EA, Skolnick P. Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 5263–5267.

85. Rossle M, Winstanely EP, Haag K, Mullen KD, Jones EA. Synaptic membrane complex carbohydrates in experimental hepatic encephalopathy. Metabolic Brain Disease 1990; 5: 119–129.

86. Rossle M, Deckert J, Mullen KD, Jones DB, Grun M, Gerok W, Jones EA. Autoradiographische bestimmung der GABAA–rezeptorendichte im gehirn von ratten mit portokavelem shunt. Zeitschrift fur Gastroenterologie 1990; 28: 142–146.

87. Baker BL, Morrow AL, Vergalla J, Paul SM, Jones EA. Gamma–aminobutyric acid (GABAA) receptor-function in a rat model of hepatic encephalopathy. Metabolic Brain Disease 1990; 5: 185–193.

88. Tsianos EV, Hoofnagle JH, Fox PC, Alspaugh M, Jones EA, Schafer DF, Moutsopoulos HM. Sjogren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990; 11: 730-734.

89. Basile AS, Hughes RD, Harrison PM, Murata Y, Pannell L, Jones EA, Williams R, Skolnick P. Elevated brain concentrations of 1,4–benzodinzepines in fulminant hepatic failure. New England Journal of Medicine 1991; 325: 473–478.

90. Talbot TL, Schmit JM, Bergasa NV, Jones EA, Walker EC. Application of piezofilm technology for the quantitative assessment of pruritus. Biomedical Instrumentation and Technology 1991; 25: 400–403.

91. Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu–opioid receptors are down–regulated in a rat model of acute cholestasis. Journal of Hepatology 1992; 15: 220-224.

92. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103: 630–635.

93. Bergasa NV, Borque MJ, Wahl LM, Rabin L, Jones EA. Modulation of thioacetamide–induced hepatocellular necrosis by prostaglandins is associated with novel histologic changes. Liver 1992; 12: 168–174.

94. Swain MG, Heyes MP, Vergalla J, Jones EA. Methionine enkephalin accumulates in plasma but not in brain or cerebrospinal fluid of rats with acute toxic hepatitis. Neuroscience Letters 1992; 141: 243–246.

95. Bergasa NV, Vergalla J, Cole KE, Wahl LM, Jones EA. 16,16–Dimethyl prostaglandin E2 modulates aflatoxin B1–induced injury of rat hepatocytes in primary culture: possible role of cAMP. Journal of Gastroenterology and Hepatology 1992; 7: 608-613.

96. Swain MG, Patchev V, Vergalla J, Chrousos G, Jones EA. Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of cholestasis. Journal of Clinical Investigation 1993; 91: 1903-1908.

97. Swain MG, Vergalla J, Bergasa NV, Jones EA. Sympathetic nerves, but not the adrenal gland, contribute to elevated plasma levels of met-enkephalin in rats with acute cholestatic hepatitis. Regulatory Peptides 1993; 46: 535-542.

98. Wahler JB, Swain MG, Carson R, Bergasa NV, Jones EA. Blood-brain barrier permeability is markedly decreased in cholestasis in the rat. Hepatology 1993; 17: 1103-1108.

99. Bergasa NV, Thomas DA, Vergalla J, Turner ML, Jones EA. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys. Life Sciences 1993; 53: 1253-1257.

100. Swain MG, Vergalla J, Jones EA. Plasma endopeptidase 24.11 ("encephalinase") activity is markedly increased in cholestatic liver disease. Hepatology 1993; 18: 556-558.

101. Basile AS, Harrison PM, Hughes RD, Gu Z-Q, Pannell L, McKinney A, Jones EA, Williams R. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994; 19: 112-121.

102. Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. Journal of Hepatology 1994; 20: 85-90.

103. Swain MG, MacArthur L, Vergalla J, Jones EA. Adrenal secretion of BAM-22P, a potent opioid peptide, is enhanced in rats with acute cholestasis. American Journal of Physiology 1994; 266: G201-G205.

104. Moreno-Otero R, Murakawa Y, Kanof ME, Civeira MP, Jones EA, James SP. Defective proliferation and regulatory function of CD4+T cells bearing Leu-8 homing receptor in primary biliary cirrhosis. Phorbol myristate acetate enhances T-cell function. Digestive Diseases and Sciences 1994; 39: 1329-1336.

105. Moreno-Otero R, Civeira MP, Suou T, Kanof ME, James SP, Jones EA. Reduced numbers of CD8+T cells and B cell-expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis. Hepato-Gastroenterology 1994; 41: 239-243.

106. Yurdaydin C, Li Y, Ha J-H, Jones EA, Rothman R, Basile AS. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: Implications for the treatment of hepatic encephalopathy with opioid antagonists. Journal of Pharmacology and Experimental Therapeutics 1995; 273: 185-192.

107. Bergasa NV, Sabol SL, Young WS III, Kleiner DE, Jones EA. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. American Journal of Physiology 1995; 268: G346-G354.

108. Yurdaydin C, Walsh TJ, Engler HD, Ha J-H, Li Y, Jones EA, Basile AS. Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Research 1995; 679: 42-48.

109. Shindo M, Mullin GE, Braun-Elwert L, Bergasa NV, Jones EA, James SP. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis and chronic hepatitis B. Clinical and Experimental Immunology 1996; 105: 254-259.

110. Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996; 16: 298-302.

111. Soini Y, Cheng CS, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, Cawley H, Welsh JA, Hansen C, Bergasa NV, Jones, EA, DiBisceglie AM, Trivers GE, Sandoval CA, Calderon IE, Munoz Espinosa LE, Harris CC. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996; 17: 1007-1012.

112. Mullen KD, Roessle M, Jones DB, Grun M, Jones EA. Precipitation of overt encephalopathy in the portacaval shunted rat: Towards the development of an adequate model of chronic portal-systemic encephalopathy. European Journal of Gastroenterology and Hepatology 1997; 9: 293-298.

113. Ferreira MR, Gammal SH, Jones EA. Resistence to 3-mercaptopropionic acid-induced seizures in hepatic encephalopathy. Hepato-Gastroenterology 1997; 44: 766-769.

114. Molenaar HAJ, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Medical and Biological Engineering and Computing 1998; 36: 220-224.

115. ter Borg F, ten Kate FJW, Cuypers HYM, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PME, Hobkoop P, Rasch MC, de Man RA, van Hattum L, Chamuleau RAFM, Reesink HW, Jones EA. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet 1998; 351: 1914-1918.

116. Yurdaydin C, Swain MG, Mininberg ED, Vergalla J, Kleiner D, Paul SM, Jones EA. Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. European Journal of Gastroenterology and Hepatology 1998; 10: 503-507.

117. van Milligen de Wit AWM, Kuiper H, Campoglio L, van Bracht J, Jones EA, Tytgat GNJ, van Deventer SJH. Does ursodeoxycholic acid mediate immunomodulalatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? European Journal of Gastroenterology and Hepatology 1999; 11: 129-136.

118. ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheim-van Dillen PM, Honkoop P, Rasch MC, de Man RA, van Hattum J, Chamuleau RA, Tytgat GN, Jones EA. A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. Journal of Clinical Pathology 2000; 53: 541-548.

119. Giger-Mateeva VI, Riemslag FCC, Reits D, Liberov B, Jones EA, Spekreijse H. Visual event-related potentials in cirrhotic patients without overt encephalopathy. Metabolic Brain Disease 2000; 15: 179-191.

120. Bergasa NV, Rothman RB, Mukerjee E, Vergalla J, Jones EA. Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: A potential mechanism for increased sensitivity to morphine in liver failure. Life Sciences 2002; 70: 1701- 1708.

121. Sanz-Cameno P, Medina J, Garcia-Buey L, Garcia-Sanchez A, Borque MJ, Martin-Vilchez S, Gamallo C, Jones EA, Moreno-Otero R. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. Journal of Hepatology 2002; 37: 723-729.

122. Wroblewski T, Rowinski O, Ziarkiewicz-Wroblewska B, Gomicka B, Albrecht J, Jones EA, Krawczyk M. Two-stage transjugular intrahepatic porta-systemic shunt for patients with cirrhosis and a high risk of portal-systemic encephalopathy as a bridge to orthotopic liver transplantation: A preliminary report. Transplantation Proceedings 2006; 38: 204-208.

123. Gomez-Dominguez E, Mendoza J, Garcia-Buey L, Trapero M, Gisbert JP, Jones EA, Moreno-Otero R. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics 2008; 27: 441-447.


CLINICAL TRIALS

1. Jones EA, Clain D, Clink HM, MacGilliray BB, Sherlock S. Hepatic coma due to acute hepatic necrosis treated by exchange blood-transfusion. Lancet 1967; ii: 169-172. (Selected summary: Gastroenterology 1968; 54: 129).

2. Hoofnagle JH, Minuk GY, Dusheiko GM, Schafer DF, Johnson R, Straus S, Jones EA, Gerin JL, Ishak K. Adenine arabinoside 5'-monophosphate for the treatment of chronic type B hepatitis. Hepatology 1982; 2: 784-788.

3. Hoofnagle JH, Hanson RG, Minuk GY, Pappas SC, Schafer DF, Dusheiko GM, Straus SE, Popper H, Jones EA. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984; 86: 150-157.

4. Pappas SC, Hoofnagle JH, Young N, Straus SE, Jones EA. Treatment of chronic non-A, non-B hepatitis with acyclovir: A pilot study. Journal of Medical Virology 1985; 15: 1-9.

5. Hoofnagle JH, Davis GL, Hanson RG, Pappas SC, Peters MG, Avigan MI, Waggoner JG, Howard R, Jones EA, Straus SE. Treatment of chronic type B hepatitis with multiple ten-day courses of adenine arabinoside monophosphate. Journal of Medical Virology 1985; 15: 121-128.

6. Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, Jones EA, Sjogren M, Seeff LB. A short course of prednisolone in chronic type B hepatitis: Report of a randomized double-blind, placebo-controlled trial. Annals of Internal Medicine 1986; 104: 12-17.

7. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, Hanson RG, Minuk GY, Dusheiko GM, Campbell G, MacSween RNM, Jones EA. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91:1327–1334.

8. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, DiBisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non–A, non–B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine 1986; 315: 1575–1578.

9. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, DiBisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. A randomized controlled trial of alpha-interferon therapy in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.

10. Bergasa NV, Talbot TL, Alling D, Schmit JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102: 544–549.

11. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritus of cholestasis: A double-blind randomized controlled trial. Annals of Internal Medicine 1995; 123: 161-167.

12. Bergasa NV, Jones EA, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH. Pilot study of low-dose oral methotrexate treatment for primary biliary cirrhosis. American Journal of Gastroenterology 1996; 91: 295-299.

13. van Milligen de Wit AWM, van Bracht J, Rauws EAJ, Jones EA, Tytgat GNJ, Huibregtse K. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointestinal Endoscopy 1996; 44: 293-299.

14. van Milligen de Wit AWM, Rauws EAJ, van Bracht J, Mulder CJJ, Jones EA, Tytgat GNJ, Huibregtse K. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointestinal Endoscopy 1997; 46: 344-347.

15. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27: 679-684.

16. Jones EA, ten Kate FJW, ter Borg F, Houben M, Reesink HW, Chamuleau RAFM. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology 1999; 11: 1165-1169.

17. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. Journal of the American Academy of Dermatology 1999; 41: 431-434.

18. Giger-Mateeva VI, Reits D, Liberov B, Jones EA, Spekreijse H. The effect of flumazenil on visual event-related potentials of clinically non-encephalopathic patients with cirrhosis. Neuroscience Letters 1999; 276: 173-176.

19. Jones EA. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. British Medical Journal (Dutch edition) 2000; 15:24II.

20. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: The avoidance of opioid withdrawal-like reactions. Quarterly Journal of Medicine 2002; 95: 547-552.

21. Jones EA, Molenaar HAJ, Oosting J. Ondansetron and puritus in chronic liver disease: a controlled study. Hepato-Gastroenterology 2007; 54: 1196-1199.


OTHER CLINICAL STUDIES

1. Jones EA, Alexander MK. Idiopathic retroperitoneal fibrosis associated with an arteritis. Annals of the Rheumatic Diseases 1966; 25: 356-360.

2. Jones EA, Crowley N, Sherlock S. Bacteraemia in association with hepatocellular and hepatobiliary disease. In: The Chemotherapy of Infections. Postgraduate Medical Journal 1967; 43 suppl: 7-ll.

3. Turnberg LA, Jones EA, Sherlock S. Biliary secretion in a patient with cystic dilation of the intrahepatic biliary tree. Gastroenterology 1968; 54: 1155-1161.

4. Neale G, Evans D, Booth CC, Creamer B, Williams ED, Hobbs JR, Hatfield FES, Douglas AP, Jones EA, Thompson G, Weinbren K, Pallis C, Harrison CV, Swallow JH. A case of adult coeliac disease resistant to treatment. British Medical Journal 1968; 2: 678-684.

5. Jones EA, Rabin L, Buckley CH, Webster GK, Owens D. Progressive intrahepatic cholestasis of infancy and childhood. Gastroenterology 1976; 71: 675-682.

6. Jones EA, Kay JM, Milligan H, Owens D. Massive infection with Fasciola hepatica in man. American Journal of Medicine 1977; 63: 836-842.

7. Chan CH, Steer CJ, Vergalla J, Jones EA. Alpha-1-antitrypsin deficiency with cirrhosis associated with the protease inhibitor phenotype SZ. American Journal of Medicine 1978; 65: 978-986.

8. Berman MD, Ishak KG, Schaefer EJ, Barnes S, Jones EA. Syndromatic hepatic ductular hypoplasia (arteriohepatic dysplasia). A clinical and hepatic histologic study of three patients. Digestive Diseases and Sciences 1981; 26: 485-497.

9. Minuk GY, Hoofnagle JH, Jones EA. Systemic side effects from the intrabiliary infusion of monooctanoin for the dissolution of gallstones. Journal of Clinical Gastroenterology 1982; 4: 133-135.

10. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Annals of Internal Medicine 1982; 96: 447-449.

11. Pappas SC, Malone DG, Rabin L, Hoofnagle JH, Jones EA. Hepatic veno-occlusive disease in a patient with systemic lupus erythematosus. Arthritis and Rheumatism 1984; 27: 104-108.

12. James SP, Jones EA, Schafer DF, Hoofnagle JH, Varma RR, Strober W. Selective IgA deficiency associated with primary biliary cirrhosis in a family with liver disease. Gastroenterology 1986; 90: 283–288.

13. Peters MG, Hoofnagle JH, McGarvey C, Fox I, Gregg RE, Jones EA. Primary biliary cirrhosis: Management of an unusual case with severe xanthomata. Journal of Clinical Gastroenterology 1989; 11: 694–697.

14. Mullen KD, Hoofnagle JH, Jones EA. Shock wave induced pancreatic trauma. American Journal of Gastroenterology 1991; 86: 630–632.

15. Jones EA, Bronkhorst CM, de Jonge E, ten Kate FJW. Sclerosing peritonitis complicated by sepsis: A potential cause of portal hypertension. European Journal of Gastroenterology and Hepatology 1998; 10: 95-98.

16. ter Borg F, Smorenburg S, de Man RA, Rietbroek RC, Chamuleau RAFM, Jones EA. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Digestive Diseases and Sciences 1998; 43: 2267-2270.

17. Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. (Research letter). Lancet 1999; 354: 397.

18. Jones EA, Dekker LRC. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000; 118: 431- 432.

19. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. European Journal of Gastroenterology and Hepatology 2001; 13: 1393-1394.

20. Lopez-Ramos D, Gabriel R, Cantero-Perona J, Moreno-Otero R, Jones EA, Mate-Jiminez J. Prevalence of appendicectomy among ulcerative colitis patients and their relatives. European Journal of Gastroenterology and Hepatology 2001; 13: 1231- 1233.

21. Jones EA, Zylicz Z. Treatment of pruritus caused by cholestasis with opioid antagonists. (Case Discussions in Palliative Medicine). Journal of Palliative Medicine 2005; 8: 1290-1294.


EDITORIALS

1. Jones EA. Hepatic scintigraphy. Gut 1967; 8: 418-420.

2. Jones EA. Immunoglobulins and malabsorption. Acta Clinica Belgica 1975; 30: 466-473.

3. Berk PD, Jones EA, Plotz PH, Seeff LB, Wright E. Corticosteroid therapy for chronic active hepatitis. Annals of Internal Medicine 1976; 85: 523-525.

4. Jones EA. Primary biliary cirrhosis and liver transplantation. New England Journal of Medicine 1982; 306: 41-43.

5. Jones EA, James SP. Circulating immune complexes and the pathogenesis of primary biliary cirrhosis. Gastroenterology 1982; 83: 709-711.

6. Jones EA. Benzodiazepine receptor ligands and hepatic encephalopathy: Further unfolding of the GABA story. Hepatology 1991; 14: 1286–1290.

7. Jones EA. Fatigue associated with chronic liver disease: A riddle wrapped in a mystery inside an enigma. Hepatology 1995; 22: 1606-1608.

8. Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut 1996; 38: 644-645.

9. Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997; 25: 492-494.

10. Jones EA. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. Journal of Hepatology 2002; 37: 863-865.

11. Jones EA. A potential novel treatment for fatigue complicating chronic liver disease: How should its efficacy be evaluated? (Personal View) Alimentary Pharmacology and Therapeurtics 2006; 23: 1113-1116.


HYPOTHESES

1. Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric acid neurotransmitter system. Lancet 1982; i: 18-20.

2. Mullen KD, Martin JV, Mendelson WB, Bassett ML, Jones EA. Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet 1988; i: 457- 459.

3. Jones EA, Bergasa NV. The pruritus of cholestasis. From bile acids to opiate agonists. Hepatology 1990; 11: 884-887.

4. Jones EA. Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C. Medical Hypotheses 2001; 57: 133-134.


CHAPTERS IN PROGRESS IN LIVER DISEASE

1. Jones EA, Vierling JM, Steer CJ, Reichen J. Cell surface receptors in the liver. In: Popper H, Schaffner F (Eds). Progress in Liver Diaseases. Volume VI. New York: Grune and Stratton, 1979: 43-80.

2. Schafer DF, Jones EA. Potential neural mechanisms in the pathogenesis of hepatic encephalopathy. In: Popper H, Schaffner F (Eds). Progress in Liver Diseases. Volume VII. New York: Grune and Stratton, 1982: 615-627.

3. Jones EA, Schafer DF. Hepatic encephalopathy: A neurochemical disorder. In: Popper H, Schaffner F (Eds). Progress in Liver Diseases. Volume VIII. New York: Grune and Stratton, 1986: 525–540.

4. Jones EA, Skolnick P. Benzodiazepine receptor ligands and the syndrome of hepatic encephalopathy. In: Popper H, Schaffner F (Eds). Progress in Liver Diseases. Volume IX. Philadelphia: WB Saunders, 1990: 345–370.


NATIONAL INSTITUTES OF HEALTH CLINICAL CONFERENCES

1. Jones EA, Frank MM, Jaffe CJ, Vierling JM. Primary biliary cirrhosis and the complement system. Jones EA (Moderator). Annals of Internal Medicine 1979; 90: 72-84.

2. Jones EA. Treatment. In: Primary biliary cirrhosis. A model autoimmune disease. James SP (Moderator). Annals of Internal Medicine 1983; 99: 500-512.

3. Jones EA, Skolnick P, Gammal SH, Basile AS, Mullen KD. The gamma-aminobutyric acid A (GABAA) receptor complex and hepatic encephalopathy. Some recent advances. Jones EA (Moderator). Annals of Internal Medicine 1989; 110: 532-546.

4. Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system. Journal of the American Medical Association 1992; 268: 3359-3362.


REVIEWS

1. Jones EA, Mandl AM. The biological basis for the use of oral contraceptives. Queen's Medical Magazine (The Journal of the University of Birmingham Medical Scool, UK) 1961; 53: 216-219.

2. Jones EA. Immunoglobulins and the gut. (Progress report). Gut 1972; 13: 825-835.

3. Berk PD, Jones EA. Production, hepatic handling and excretion of bilirubin. In: Altman PL, Katz DD (Eds). Human Health and Disease. Bethesda, MD: Federation of American Societies for Experimental Biology, 1977: 209-210.

4. Jones EA, Berk PD. Liver diagnostic tests. In: Altman PL, Katz DD (Eds). Human Health and Disease. Bethesda, MD: Federation of American Societies for Experimental Biology, 1977: 211-214.

5. Wright EC, Seeff LB, Berk PD, Jones EA, Plotz PH. Treatment of chronic active hepatitis: An analysis of three controlled trials. (Clinical trends and topics). Gastroenterology 1977; 73: 1422-1430.

6. Carson ER, Jones EA. The use of kinetic analysis and mathematical modeling in the study of metabolic pathways in vivo. Applications to hepatic organic anion metabolism. Part I. New England Journal of Medicine 1979; 300: 1016-1027.

7. Carson ER, Jones EA. The use of kinetic analysis and mathematical modelling in the study of metabolic pathways in vivo. Applications to hepatic organic anion metabolism. Part II. New England Journal of Medicine 1979; 300: 1078-1086.

8. Lawley TJ, James SP, Jones EA. Circulating immune complexes: Their detection and potential significance in some hepatobiliary and intestinal diseases. (Progress article). Gastroenterology 1980; 78: 626-641.

9. James SH, Hoofnagle JH, Strober W, Jones EA. Primary biliary cirrhosis: A model autoimmune disease. Annals of Internal Medicine 1983; 99: 500-512.

10. Pappas SC, Jones EA. Methods for assessing hepatic encephalopathy. In: Preisig R (Ed). Clinical Evaluation of Hepatic Function. Seminars in Liver Disease 1983; 3: 298-307.

11. Jones EA. Hepatic sinusoidal cells: New insights and controversies. Hepatology 1983; 3: 259-266.

12. Jones EA, Schafer DF, Ferenci P, Pappas SC. The GABA hypothesis of the pathogenesis of hepatic encephalopathy: Current status. The Yale Journal of Biology and Medicine 1984; 57: 301-316.

13. Jones EA, Schafer DF, Ferenci P, Pappas SC. The neurobiology of hepatic encephalopathy. (Special article). Hepatology 1984; 4: 1235-1242.

14. Jones EA, Ferenci P, Pappas SC, Schafer DF. Pathogenese der hepatischen Enzephalopathie - Untersuchungen an einem Kaninchenmodell des akuten Leberversagunens. Leber Magen Darm 1984; 14: 282-287.

15. Jones EA, Summerfield JA. Functional aspects of hepatic sinusoidal cells. In: Popper H (Ed). Basic Science and the Future of Hepatology. Seminars in Liver Disease 1985; 5: 157-174.

16. Jones EA, Bassett ML, Mullen KD. Hepatic encephalopathy. In: Arias IM, Frenkel M, Wilson JHP (Eds). The Liver Annual / 5. Amsterdam: Elsevier Science, 1986: 274-313.

17. Jones EA. Hepatic encephalopathy: An update. Viewpoints in Digestive Diseases 1986; 18: 1-4.

18. Summerfield JA, Jones EA. Further progress towards understanding hepatic sinusoidal cells. Journal of Hepatology 1986; 3: 413–418.

19. Jones EA, Mullen KD, Gammal SH. Hepatic encephalopathy. In: Arias IM, Frenkel M, Wilson JHP (Eds). The Liver Annual / 6. Amsterdam: Elsevier Science, 1987: 396- 422.

20. Basile AS, Jones EA. Hepatic encephalopathy and the GABA/benzodiazepine receptor chloride ionophore complex: An update. Journal of Gastroenterology and Hepatology 1988; 3: 383–394.

21. Jones EA, Gammal SH, Martin P. Hepatic encephalopathy: New light on an old problem. Quarterly Journal of Medicine 1988; 69: 851–867.

22. Sorrentino D, Jones EA, Berk PD. Familial hyperbilirubinemia syndromes: Kinetic approaches. In: Bouchier IAD (Ed). Jaundice. Ballieres Clinical Gastroenterology 1989; 3: 313-336.

23. Gammal SH, Jones EA. Hepatic encephalopathy. In: Rustgi VK (Ed). Update on Liver Disease. Medical Clinics of North America 1989; 73: 793–813.

24. Moreno–Otero R, Lisker–Melman M, Jones EA. Primary biliary cirrhosis. In: Rustgi VK (Ed). Update on Liver Disease. Medical Clinics of North America 1989; 73: 911–929.

25. Jones EA, Basile AS, Mullen KD, Gammal SH. Flumazenil: potential implications for hepatic encephalopathy. Pharmacology and Therapeutics 1990; 45: 331–343.

26. Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: Evidence for the involvement of benzodiazepine receptor ligands. Pharmacological Reviews 1991; 43: 27–71.

27. Bergasa NV, Jones EA. Management of the pruritus of cholestasis: Potential role of opiate antagonists. (GI drug column). American Journal of Gastroenterology 1991; 86: 1404–1412.

28. Bergasa NV, Jones EA. The pruritus of cholestasis. In: Schiff ER (Ed). Management of Difficult Problems in Hepatology. Seminars in Liver Disease 1993; 13: 319-327.

29. Jones EA, Basile AS, Yurdaydin C, Skolnick P. Do benzodiazepine ligands contribute to hepatic encephalopathy? Advances in Experimental Medicine and Biology 1993; 341:57-69.

30. Jones EA, Bergasa NV. Immunosuppressive treatment of chronic liver disease. In: Allison AC, Lafferty KJ, Fliri H (Eds). Immunosuppressive and Anti-Inflammatory Drugs. Annals of the New York Academy of Sciences 1993; 696: 319-327.

31. Bergasa NV, Jones EA. The pruritus of cholestasis: Potential pathogenic and therapeutic implications of opioids. (Viewpoints on digestive diseases). Gastroenterology 1995; 108: 1582-1588.

32. van Nieuwkerk CMJ, Rauws EAJ, Tytgat GNJ, Reeders JWA., Jones EA, Gouma DJ. Veranderde diagnostiek en behandeling van hepatocellulair carcinoom. Nederlands Tijdschrift voor Geneeskunde 1996; 140: 922-926.

33. Mullen KD, Jones EA. Natural benzodiazepines and hepatic encephalopathy. In: Blei AT, Butterworth RF (Eds). Hepatic Encephalopathy. Seminars in Liver Disease 1996; 16: 255-264.

34. Sallie RW, Jones EA. Molecular biology of hepatic drug reactions. In: Cameron RG, Feuer G, de la Iglesia FA (Eds). Drug-Induced Hepatotoxicity. Handbook of Experimental Pharmacology 1996; 121: 75-97.

35. Jones EA, Bergasa NV. Towards understanding the pathogenesis of the pruritus of cholestasis and rationalising its treatment. Turkish Journal of Gastroenterology 1996; 7: 275-281.

36. Basile AS, Jones EA. Ammonia and GABAergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997; 25: 1303-1305.

37. Jones EA, Weissenborn K. Neurology and the liver. Journal of Neurology, Neurosurgery, and Psychiatry 1997; 63: 279-293.

38. Bergasa NV, Jones EA. The pruritus of cholestasis: Evolving pathogenic concepts suggest new therapeutic options. In: Lindor KD, Dickson ER (Eds). Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Adult Cholangiopathies. Clinics in Liver Disease 1998; 2: 391-405.

39. Marsman WA, Oude Elferink RPJ, Jones EA. Jeuk en leverziekten. Krabben is te meten; jeuk niet. Pharmaceutisch Weekblad 1999; 134: 324-328.

40. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29: 1003-1006.

41. Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. In: Jansen PLM (Ed). Review in Depth: Primary Biliary Cirrhosis. European Journal of Gastroenterology and Hepatology 1999; 11: 623-631.

42. Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. Journal of the Neurological Sciences 1999; 170: 138-146.

43. Jones EA, Begasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Canadian Journal of Gastroenterology 2000; 14: 33-40.

44. Jones EA. Pathogenesis of hepatic encephalopathy. In: Herrera J (Ed). Pathophysiology of Liver Disease. Clinics in Liver Disease 2000; 4: 467-485.

45. Jones EA. Fatigue associated with chronic hepatitis C. The Hep C Review (Hepatitis C Council of New South Wales, Australia) 2000; 30: 16-17.

46. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. In: Jansen P (Ed). Primary Biliary Cirrhosis. Ballieres Best Practice and Research: Clinical Gastroenterology 2000; 14: 643-655.

47. Medina J, Jones EA, Garcia-Monzon C, Moreno-Otero R. Immunopathogenesis of cholestatic autoimmune liver diseases. European Journal of Clinical Investigation 2001; 31: 64-71.

48. Jones EA. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. (Perspectives in clinical hepatology). Hepatology 2002; 35: 258-262.

49. Jones EA, Lavini C. Is cerebral edema a component of the syndrome of hepatic encephalopathy? Hepatology 2002; 35: 1270-1273.

50. Jones EA. Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metabolic Brain Disease 2002; 17: 275-281.

51. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, Zylicz Z. Itch: scratching more than the surface. Quarterly Journal of Medicine 2003; 96: 7-26.

52. Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R. Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Alimentary Pharmacology and Therapeutics 2003; 17: 17-27 .

53. Jones EA. Rationale for treating pruritus complicating chronic liver disease with opiate antagonists. Current Gastroenterology Reports 2004; 6: 87-88.

54. Jones EA. Pruritus and fatigue associated with liver disease: is there a role for ondansetron? Expert Opinion on Pharmacotherapy 2008; 9: 645-651.

55. Gonzalez-Casas R, Moreno-Otero R, Jones EA, Gisbert JP, Garcia-Buey L. Hepatitis-associated aplastic anemia: a syndrome associated with abnormal immunologic function. Alimentary Pharmacology and Therapeutics 2009; 30: 436-443.

56. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World Journal of Gastroenterology 2009; 15: 4653-4658.


INTERNET PUBLICATION (review)

1. Jones EA. Management of ascites complicating cirrhosis in adults. OMGE Practice Guidelines 2001, www.omge.org


MEDICAL EDUCATION

1. Schiff ER, Sorrell MF, Berk PD, Combes B, Fallon H, Gollan J, Jones EA, Maddrey WC, Scharschmidt BF, Tamburro C (Ad Hoc Committee for Hepatology Training of the American Association for the Study of Liver Diseases). Guidelines for training in hepatology. Hepatology 1992; 16: 1084-1086.


DRUG REGULATION

1. Reginster J-Y, Compston JE, Jones EA, Kaufman JM, Audran M, Bouvenot G, Frati L, Mazzuoli G, Gennari C, Lemmel E-M, Ringe JD, Sebert J-L, Vanhaelst L, Avouac B. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcified Tissue International 1995; 57: 247-250.

2. Compston JE, Audran M, Avouac B, Bouvenot G, Devogelaer JP, Eastell R, Fabris F, Gennari C, Jones EA, Kaufman JM, Lemmel EM, Mazzuoli G, Reid DM, Ringe JD, Vanhaelst L, Ziegler R, Reginster J-Y. Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis. Calcified Tissue International 1996; 59: 323-327.

3. Dougados M, Devogelaer JP, Annefeld M, Avouac B, Bouvenot G, Cooper C, Dieppe P, Ethgen D, Garattini S, Jones EA, Kaufman JM, Leeming M, Lemmel EM, Lohmander S, Menkes CJ, Nuki G, Paolozzi L, Pujol JP, Rovati L, Serni U, Spector T, Tsouderos Y, Veys EM, Weseloh G, Reginster J-Y. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Annals of the Rheumatic Diseases 1996; 55: 552-557.


FORWARDS

1. Jones EA. Primary biliary cirrhosis: A challenging disease for hepatologists and immunologists. In: Jones EA (Ed). Primary Biliary Cirrhosis. Seminars in Liver Disease. 1981; 1: 267-272.

2. Hoofnagle JH, Jones EA. Therapy of chronic viral hepatitis: Past, present and future. In: Hoofnagle JH, Jones EA (Eds). Interferon Therapy of Chronic Viral Hepatitis. Seminars in Liver Disease 1989; 9: 231–234.


CHAPTERS IN TEXTBOOKS

1. Wood EJ, Jones EA, Kreel L. Comparison between scintillation scanning and arteriography in liver disease with special reference to space-occupying lesions. In: Medical Radioisotope Scintigraphy. Volume 2. Vienna: International Atomic Energy Agency, 1968: 545-560.

2. Jones EA, Carson ER, Rosenoer VM. An approach to the investigation of the dynamic structure of a complex biological system incorporating state variable diagram analysis. In: Rothschild MA, Waldmann TA (Eds). Plasma Protein Metabolism. New York: Academic Press, 1970: 11-23.

3. Jones EA, Bloomer JR, Berk PD, Carson ER, Owens D, Berlin NI. The quantitation of hepatic bilirubin synthesis in man. In: Berk PD, Berlin NI (Eds). The Chemistry and Physiology of Bile Pigments. Washington DC: US Department of Health, Education and Welfare, U S Government Printing Office, 1977: 189-205.

4. Jones EA, Berk PD. Liver function. In: Brown SS, Mitchell FL, Young DS (Eds). Chemical Diagnosis of Disease. Amsterdam: Elsevier, 1979: 525-662.

5. Berk PD, Jones EA, Howe RB, Berlin NI. Disorders of bilirubin metabolism. In: Bondy PK, Rosenberg L (Eds). Metabolic Control and Disease. 8th edition. Philadelphia: W B Saunders, 1979: 1009-1088.

6. Jones EA, James SP, Vierling JM. Immunologic function in primary biliary cirrhosis: Defects recently demonstrated at the National Institutes of Health. In: Berk PD, Chalmers TC (Eds). Frontiers in Liver Disease. New York: Thieme-Stratton, 1981: 283-304.

7. Jones EA, Rosenoer VM. Corticosteroid therapy in acute and chronic hepatitis. In: Rosenoer VM, Rothschild MA (Eds). Current Controversies in Clinical Care. New York: Spectrum Publications, 1981: 79-103.

8. Dusheiko GM, Jones EA. Management of non-A, non-B hepatitis. In: Gerety RJ (Ed). Non-A, Non-B Hepatitis. New York: Academic Press, 1981: 251-270.

9. Jones EA, Schafer DF. Fulminant hepatic failure. In: Zakim D, Boyer TD (Eds). Hepatology: A Textbook of Liver Disease. First edition. Philadelphia: W B Saunders, 1982: 415-445.

10. Jones EA, Carson ER, Berk PD. The role of kinetic analysis and mathematical modeling in the study of bilirubin metabolism in vivo. In: Heirwegh KPM, Brown SB (Eds). Bilirubin, Volume 2: Metabolism. Boca Raton, FL: CRC Press, 1982: 133-172.

11. Jones EA, Summerfield JA. Kupffer cells. In: Arias IM, Popper H, Schacter D, Shafritz DA (Eds). The Liver: Biology and Pathobiology. First edition. New York: Raven Press, 1982: 507-524.

12. Jones EA. Primary biliary cirrhosis: Potential pathogenic mechanisms and the effects of therapies on the disease process. In: Thomas HC, MacSween RNM (Eds). Recent Advances in Hepatology. Volume l. Edinburgh: Churchill Livingstone, 1983: 131-151.

13. Jones EA. Primary biliary cirrhosis. In: Fauci AS, Lichtenstein LM (Eds). Current Therapy in Allergy, Immunology and Rheumatology. St Louis, MO: CV Mosby, 1985: 179-182.

14. Berk PD, Isola LM, Jones EA. Specific defects in hepatic storage and clearance of bilirubin. In: Ostrow JD (Ed). Bile Pigments and Jaundice. New York: Marcel Dekker, 1986: 279–316.

15. Jones EA. Potential neural mechanisms in the mediation of hepatic encephalopathy. In: Williams R (Ed). Liver Failure. Clinics in Critical Care Medicine. Ledingham IM, Grenvik A (General Eds). Edinburgh: Churchill Livingstone, 1986: 4-25.

16. Jones EA, Carson ER, Berk PD. Quantitation of bilirubin metabolism in vivo. Kinetic studies and mathematical modeling. In: Ostrow J D (Ed). Bile Pigments and Jaundice. New York: Marcel Dekker, 1986: 439–474.

17. Jones EA, Mullen KD, Jones DB. The encephalopathy of hepatic failure. In: Coyle JT (Ed). Models of Dementia: A Synaptic Neurochemical Perspective. New York: Alan R Liss, 1987: 137-161.

18. Jones EA, Summerfield JA. Kupffer cells. In: Arias IM, Jakoby WB, Popper H, Schacter D, Shafritz DA (Eds). The Liver: Biology and Pathobiology. Second edition. New York: Raven Press, 1988: 683–704.

19. Jones EA, Gammal SH. Hepatic encephalopathy. In: Arias IM, Jakoby WB, Popper H, Schacter D, Shafritz DA (Eds). The Liver: Biology and Pathobiology. Second edition. New York: Raven Press, 1988: 985–1005.

20. Jones EA. Hepatic encephalopathy and GABA–ergic neurotransmission. In: Conn HO, Bircher J (Eds). Hepatic Encephalopathy: Management with Lactulose and Related Carbohydrates. East Lancing, MI: Medi–Ed Press, 1988: 61–80.

21. Jones EA, Gammal SH. Hepatic encephalopathy. In: Cohen RD, Lewis B, Alberti KGMM, Dehman AM (Eds). The Metabolic and Molecular Basis of Acquired Disease. London: Balliere Tindall, 1990: 1246–1279.

22. Jones EA, Schafer DF. Fulminant hepatic failure. In: Zakim D, Boyer TD (Eds). Hepatology: A Textbook of Liver Disease. Second edition. Philadelphia: WB Saunders, 1990: 460–492.

23. Schafer DF, Jones EA. Hepatic encephalopathy. In: Zakim D, Boyer TD (Eds). Hepatology: A Textbook of Liver Disease. Second edition. Philadelphia: WB Saunders, 1990: 447–460.

24. Jones EA, Bergasa NV. Fulminant hepatic failure. In: Taylor RW, Shoemaker WC (Eds). Critical Care: State of the Art. Volume 12. Fullerton, CA: The Society of Critical Care Medicine, 1991: 509–539.

25. Jones EA, Ferenci P. Hepatic encephalopathy, GABAergic neurotransmission and the benzodiazepines. In: Conn, HO, Bircher J (Eds). Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, IL: Medi–Ed Press, 1994: 75-100.

26. Yurdaydin C, Jones E.A. Hepatic encephalopathy. In: Gitnick G, Hollander D, Samloff IM, Schoenfield LJ, Vierling JM (Eds). Principles and Practice of Gastroenterology and Hepatology. Second edition. Norwalk, CT: Appleton and Lange, 1994: 885-895.

27. Jones EA, Mullen KD. Management of hepatic encephalopathy. In: Lewis JH (Ed). A Pharmacological Approach to Gastrointestinal Diseases. Baltimore: Williams and Wilkins, 1994: 377-396.

28. Bergasa NV, Jones EA. Pruritus of cholestasis: Empiric therapeutic approaches and rationale for use of opioid antagonists. In: Lewis JH (Ed). A Pharmacological Approach to Gastrointestinal Diseases. Baltimore: Williams and Wilkins, 1994: 397-413.

29. Jones EA. Hepatocellular failure. In: Weatherall DJ, Ledingham J, Warrell D (Eds). Oxford Textbook of Medicine. Third edition. Oxford: Oxford University Press, 1996: 2100-2111.

30. Bergasa NV, Jones EA. The pruritus of cholestasis: Behavioral studies shed light on its pathogenesis. In: Lindor KD, Heathcote EJ, Poupon R (Eds). Primary Biliary Cirrhosis: From Pathogenesis to Clinical Treatment. Boston: Kluwer Academic, 1998: 108-114.

31. Jones EA, Weissenborn K. Neurology and the liver. In: Hughes RAC, Perkin GD, (Eds). Neurology and Medicine. London: BMJ Books, 1999: 240-277.

32. Jones EA. Hepatocellular failure. In: Ledingham JGG, Warrell DA (Eds). Concise Oxford Textbook of Medicine. Oxford: Oxford University Press, 2000: 639-643.

33. Jones EA. Hepatocellular failure. In: Warrell DA, Cox TM, Firth JD, Benz EJ (Eds). Oxford Textbook of Medicine. Fourth edition. Oxford: Oxford University Press, 2003: 741-751.

34. Bergasa NV, Jones EA. Prutitus complicating liver disease. In: Yosipovitch G, Greaves MW, Fleischer AB, McGlone F (Eds). Itch: Basic Mechanisms and Therapy. New York: Marcel Dekker, 2004: 211-224.

35. Jones EA, Molenaar H, Bergasa NV. Measurement of scratching activity. In: Zylicz Z, Twycross R, Jones EA (Eds). Pruritus in Advanced Disease. Oxford: Oxford University Press, 2004: 46-55.

36. Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid neurotransmitter system. In: Zylicz Z, Twycross R, Jones EA (Eds). Pruritus in Advanced Disease. Oxford: Oxford University Press, 2004: 56-68.

37. Jones EA. Hepatocellular failure. In: Warrell DA, Cox TM, Firth JD (Eds). Oxford Textbook of Medicine. Fifth edition. Oxford: Oxford University Press (submitted).

PROCEEDINGS OF INTERNATIONAL SYMPOSIA

1. Mandl AM, Beaumont HM, Hughes GC, Harding LK, Jones EA. The differential radiosensitivity of male primordial germ cells and spermatogonia. In: Carlson WD, Gassner FX (Eds). Effects of Ionizing Radiation on the Reproductive System. New York: MacMillan, 1964: 165-174.

2. Jones EA, Jirsa M. Liver scintigraphy with special reference to the use of 131I-bromsulphthalein. In: Read AE (Ed). The Liver. Colston Papers, volume 19. London: Butterworths, 1967: 139-152.

3. Sherlock S, Jones EA, Crowley N. Bacteraemia in patients with hepato-biliary disease. In: Linder J, Hamburg-Eppendorf, Wilhelmi E (Eds). Infective Inflammation. Stuttgart: Hans Huber, 1968: 303-310.

4. Cragie A, Jones EA, Rosenoer VM, Smallwood RA, Tavill AS. Albumin synthesis in liver disease. In: Birke G, Norburg R, Plantin LO (Eds). Physiology and Pathophysiology of Protein Metabolism. Oxford: Pergamon Press, 1969: 61-73.

5. Barr CD, Carson ER, Finkelstein L, Jones EA. A study of the dynamics of plasma protein metabolism. Fourth Congress of the International Federation of Automatic Control Bionics. Technical Session No. 70, Paper No. 70.6. Warsaw: Wydawnictwa Czasopism Technicznych NOT, 1969: 87-100.

6. Jones EA. Treatment of acute hepatic failure by exchange blood transfusion. In: Boeckl O, Hell E, Steiner H (Eds). Possibilities of Liver Replacement. Munich: Urban and Schwarzenberg, 1970: 214-220.

7. Waldmann TA, Jones EA. The role of cell-surface receptors in the transport and catabolism of immunoglobulins. In: Wolstenholme GEW, O'Connor M (Eds). Protein Turnover. Ciba Foundation Symposium, volume 9 (new series). Amsterdam: Associated Scientific Publishers, 1972: 5-23.

8. Owens D, Jones EA, Richards TG, Carson ER. Studies of the kinetics of 14C-unconjugated bilirubin metabolism in cirrhosis. In: Bakken A, Fog J (Eds). Metabolism and Chemistry of Bilirubin and Related Tetrapyrroles. Oslo: Oslo Pediatric Institution, 1975: 179-186.

9. Balfour AH, Jones EA. The binding of IgG to human placental membranes. In: Hemmings WA (Ed). Maternofoetal Transmission of Immunoglobulins. London: Cambridge University Press, 1975: 61-75.

10. Waldmann TA, Jones EA. The role of IgG-specific cell surface receptors in IgG transport and catabolism. In: Hemmings WA (Ed). Maternofoetal Transmission of Immunoglobulins. London: Cambridge University Press, 1975: 123-136.

11. Jones EA, Plotkin C, Teychenne PF, Ishak KG, Calne DB. The hepatotoxicity of ergot alkaloids. In: Fuxe F, Calne DB (Eds). Dopaminergic Ergot Derivatives and Motor Function. Oxford: Pergamon Press, 1979: 415-429.

12. Zeneroli ML, Waggoner JG, Schafer DF, Kolobow T, Jones EA. Development of an extracorporeal hepatic support device: Clearance of amino acids, short chain fatty acids and neurotransmitters by different carbons. In: Aminoacidi ed Encefalopatia Epatica. Pisa: Pacini Editore, 1979: 81-93.

13. Berk PD, Schafer DF, Blitzer BL, Jones EA. Computer models and animal models: The rational stepwise approach to the development of artificial hepatic support systems for the treatment of fulminant hepatic failure. In: Sideman S, Chang TMS (Eds). Hemoperfusion: Kidney and Liver Supports and Detoxification. Washington DC: Hemisphere Publishing Corporation, 1980: 151-174.

14. Jones EA, Vierling JM, Steer CJ. Surface receptors on hepatic sinusoidal cells. In: Bianchi L, Gudat F, Reutter W (Eds). Communication of Liver Cells. Falk Symposium No. 27. Lancaster, UK: MTP Press, 1980: 211-227.

15. Zeneroli ML, Schafer DF, Waggoner JG, Jones EA. Hemoperfusion-induced respiratory distress syndrome in an animal model: The effects of corticosteroids. In: Brunner G, Schmidt FW (Eds). Artificial Liver Support. New York: Springer Verlag, 1981: 188-197.

16. Jones EA. Primary biliary cirrhosis: A syndrome of intractable intrahepatic cholestasis and a model autoimmune disease. Seoul International Liver Symposium. Seoul, South Korea, 1982: 99-119.

17. Jones EA, Schafer DF. Recent concepts relating to the pathogenesis of hepatic encephalopathy. Seoul International Liver Symposium. Seoul, South Korea, 1982: 223-234.

18. Jones EA. The enigma of hepatic encephalopathy. In: McIntyre N, Hoffbrand BI (Eds). Festschrift for Dame Sheila Sherlock. Postgraduate Medical Journal 1983; 59 suppl 4: 42-54.

19. Jones EA, Vergalla J, Summerfield JA. Carbohydrate specificities of a glycoprotein recognition system on hepatic endothelial cells. In: Popper H, Reutter W, Gudat F, Kottgen E (Eds). Structural Carbohydrates in the Liver. Falk Symposium No. 34. Lancaster, UK: MTP Press, 1983: 287-299.

20. Summerfield JA, Vergalla J, Jones EA. Modulation of a glycoprotein recognition system on hepatic sinusoidal cells by diabetes mellitus and fasting. In: Popper H, Reutter W, Gudat F, Kottgen E (Eds). Structural Carbohydrates in the Liver. Falk Symposium No. 34. Lancaster, UK: MTP Press, 1983: 455-465.

21. Jones EA. Potential roles for synergism between neurotoxins and for GABA-ergic neural inhibition in the pathogenesis of hepatic coma. In: Conn HO (Moderator). Round Table on Hepatic Coma. In: Bianchi L, Gerok W, Sickinger K, Stelder GA (Eds). Liver in Metabolic Disease. Falk Symposium No. 35. Lancaster, UK: MTP Press, 1983: 173-176.

22. Evans ND, Carson ER, Cramp DG, Jones EA. Bilirubin dynamics: good modelling practice. In: van Bemmel JH, Ball MJ, Wigertz O (Eds). Proceedings of the Fourth World Conference on Medical Informatics (MEDINFO 83). Participant's edition, Part 2. Amsterdam: North Holland, 1983: 863-866.

23. Ferenci P, Schafer DF, Pappas SC, Jones EA. Inhibitory and excitatory aminoacid neurotransmitters in hepatic coma. In: Kleinberger G, Deutsch E (Eds). New Aspects of Clinical Nutrition. Basel: S Karger, 1983: 485-504.

24. Summerfield JA, Vergalla J, Jones EA. A glucose sensitive glycoprotein recognition system on rat hepatic endothelial cells. In: Reid E, Cook GMW, Moore DJ (Eds). Investigation of Membrane-Located Receptors. New York: Plenum Press, 1984: 303-309.

25. Ferenci P, Pappas SC, Jones EA. Hepatic encephalopathy is associated with decreased numbers of receptors for excitatory aminoacid neurotransmitters. In: Capocaccia L, Fischer JE, Rossi-Fanelli F (Eds). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum, 1984: 121-125.

26. Pappas SC, Ferenci P, Jones EA. Hepatic encephalopathy. A disorder of synaptic plasma membrane composition and fluidity? In: Kleinberger G, Ferenci P, Riederer P, Thaler H (Eds). Advances in Hepatic Encephalopathy and Urea Cycle Diseases. New York: S. Karger, 1984: 331-336.

27. Jones EA, Schafer DF, Ferenci P, Pappas SC. Changes in the status of brain receptors for neurotransmitters in a rabbit model of hepatic coma: Their potential significance. In: Kleinberger G, Ferenci P, Riederer P, Thaler H (Eds). Advances in Hepatic Encephalopathy and Urea Cycle Diseases. New York: S Karger, 1984: 337-352.

28. Ferenci P, Pappas SC, Jones EA. Neurotransmitter receptor changes in experimental hyperammonemia in the rabbit. In: Kleinberger G, Ferenci P, Riederer P, Thaler H (Eds). Advances in Hepatic Encephalopathy and Urea Cycle Diseases. New York: S Karger, 1984: 368-372.

29. Ferenci P, Riederer P, Pappas SC, Jones EA. Effects of branched chain amino acids on ammonia-induced changes in neurotransmission. In: Adibi SA, Fekl W, Langenbeck U, Schauder P (Eds). Branched Chain Amino and Keto Acids in Health and Disease. Basel: S Karger, 1984: 472-482.

30. Jones EA, Pappas SC, Ferenci P, Schafer DF. Hepatic encephalopathy: Testing the validity of hypotheses of its pathogenesis. In: Brunner H, Thaler H (Eds). Hepatology: A Festschrift for Hans Popper. New York: Raven, 1985: 223-230.

31. Jones EA. Recent trends in studies of the pathogenesis of hepatic encephalopathy. In: Bianchi L, Gerok W, Popper H (Eds). Trends in Hepatology. A symposium in honor of Herbert Falk on the occasion of his 60th birthday. Lancaster, UK: MTP Press, 1985: 119-127.

32. Jones EA. Hepatic encephalopathy: state of the art. In: Kirsch RE, Kruskal JB, Czomos G, Terblanche J (Eds). Liver Update 2/1985. Philadelphia: Balliere Tindall, 1985: 132-140.

33. Pappas SC, Jones EA, Schafer DF, Berk PD. Artificial liver support: Functional requirements and research strategies for future development. In: Nose Y, Kjellstrand C, Ivanovitch P (Eds). Progress in Artificial Organs - 1985. Cleveland, OH: International Society of Artificial Organs, 1986: 721–725.

34. Jones EA. Modulation of the functions of hepatic sinusoidal cells. In: Reutter W, Popper H, Arias IM, Heinrich PC, Keppler D, Landmann L (Eds). Modulation of Liver Cell Expression. Falk Symposium No. 43. Lancaster, UK: MTP Press, 1987: 69-79.

35. Jones EA. Artificial support in liver failure. In: Schreiner GE (Ed). The Role of Hemoperfusion in Acute Liver Failure. Princeton Junction, NJ: Communications Media for Education, 1987: 6–7.

36. Jones EA. Evolving trends in studies of the pathogenesis of hepatic encephalopathy. In: Tygstrup N, Orlandi F (Eds). Cirrhosis of the Liver: Methods and Fields of Research. Amsterdam: Elsevier Science, 1987: 259–274.

37. Mullen KD, Schafer DF, Cuchi P, Roessle M, Maynard TF, Jones EA. Evaluation of the suitability of galactosamine–induced fulminant hepatic failure as a model of hepatic encephalopathy in the rat and the rabbit. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E (Eds). Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier Science, 1988: 205–212.

38. Geller D, Gammal SH, Mullen KD, Jones EA. An improved rat model of hepatic encephalopathy due to fulminant hepatic failure: The importance of supportive therapy. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E, (Eds). Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier Science, 1988: 213–217.

39. Roessle M, Mullen KD, Jones EA. Benzodiazepine receptors in a model of acute hepatic encephalopathy: Effect of Triton on receptor solubilization. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E (Eds). Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier Science, 1988: 243-247.

40. Gammal SH, Jones EA, Bassett ML, Mullen KD, Geller D, Skolnick P. Antagonists of the GABA/benzodiazepine receptor complex ameliorate hepatic encephalopathy in two models of fulminant hepatic failure. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E (Eds). Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier Science, 1988: 325–332.

41. Mullen KD, Martin JV, Mendelson WB, Jones EA. Further evidence that hepatic encephalopathy in the galactosamine rabbit model may be mediated by an endogenous benzodiazepine compound. In: Soeters PB, Wilson JHP, Meijer AJ, Holm E (Eds). Advances in Ammonia Metabolism and Hepatic Encephalopathy. Amsterdam: Elsevier Science, 1988: 333–337.

42. Kassianides C, DiBisceglie AM, Hoofnagle JH, Mullen K, Peters M, Rustgi V, Jones DB, Lisker–Melman M, Park Y, Waggoner JG, Jones EA. Alpha-interferon therapy in patients with decompensated chronic type B hepatitis. In: Zuckerman AJ (Ed). Viral Hepatitis and Liver Disease. New York: Alan R Liss, 1988: 840–843.

43. Martin P, Ferreira MR, Gammal SH, Fromm HC, Jones EA. The rat with carbon tetrachloride induced cirrhosis as a model of hepatic encephalopathy. In: Butterworth RF, Layrargues GP (Eds). Hepatic Encephalopathy. Pathophysiology and Treatment. Clifton NJ: Humana Press, 1989: 261–270.

44. Jones EA, Gammal SH, Basile AS, Mullen KD, Bassett ML, Schafer DF, Skolnick P. Hepatic encephalopathy and benzodiazepine receptor ligands. In: Butterworth RF, Layrargues GP (Eds). Hepatic Encephalopathy. Pathophysiology and Treatment. Clifton, NJ: Humana Press, 1989: 273–286.

45. Gammal SH, Basile AS, Skolnick P, Jones EA. Isolated CNS neurons from a model of hepatic encephalopathy exhibit increased sensitivity to a benzodiazepine. In: Butterworth RF, Layrargues GP (Eds). Hepatic Encephalopathy. Pathophysiology and Treatment. Clifton, NJ: Humana Press, 1989: 295–303.

46. Jones EA. Hepatic encephalopathy: GABAergic neurotransmission. In: Tandon BN, Nayak NC, Nundy S (Eds). Advances in Liver Diseases. New Delhi: Macmillan India, 1989: 273–297.

47. Jones EA, Basile AS, Skolnick P. Hepatic encephalopathy, GABA–ergic neurotransmission and benzodiazepine receptor ligands. In: Grisolia S, Felipo V, Minana MD (Eds). Cirrhosis, Hepatic Encephalopathy, and Ammonium Toxicity. Advances in Experimental Biology and Medicine 1990; 272: 121-134.

48. Basile AS, Ostrowski NL, Gammal SH, Jones EA, Skolnick P. The involvement of the benzodiazepine receptor in hepatic encephalopathy: Evidence for the presence of a benzodiazepine receptor ligand. In: Biggio G, Costa E (Eds). GABA and Benzodiazepine Receptor Subtypes. Advances in Biochemical Psychopharmacology 1990; 46: 189–200.

49. Basile AS, Skolnick P, Jones EA. Benzodiazepine receptor ligands and hepatic encephalopathy: Electrophysiological and neurochemical studies. In: Bengtsson F, Jeppsson B, Almdal T, Vilstrup H (Eds). Progress in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, 1991: 131–136.

50. Jones EA (chairman). Round table discussion on benzodiazepine antagonists. In: Bengtsson F, Jeppsson B, Almdal T, Vilstrup H (Eds). Progress in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, 1991: 169-179.

51. Basile AS, Pannell L, Jaouni T, Gammal SH, Jones EA, Fales HM, Skolnick P. Benzodiazepine receptor ligands are elevated in hepatic encephalopathy. In: Bernard EA, Costa E (Eds). Transmitter Amino Acid Receptors: Structures, Transduction and Models for Drug Development. New York: Thieme Medical, 1991: 305–323.

52. Hovorka R, Fried M, Jones EA, DiBisceglie AM, Carson ER. Modelling of lidocaine–MEGX kinetics to assess impairment of liver function. In: Bracale M, Denoth F (Eds). Proceedings of the VI Mediteranean Conference on Medical and Biological Engineering (MEDICON 92). Pisa: Area di Ricerca - CNR, 1992: 85-88.

53. Jones EA, Yurdaydin C, Basile AS. The role of endogenous benzodiazepines in hepatic encephalopathy: animal studies. In: Taberner PV, Badawy AA (Eds). Advances in Biomedical Alcohol Research. Proceedings of the 6th ISBRA Congress. Alcohol and Alcoholism 1993; 2 suppl: 175-180.

54. Bergasa NV, Vergalla J, Turner ML, Loh PY, Jones EA. Alpha melanocyte-stimulating hormone in primary biliary cirrhosis. In: Vaudry H, Eberle AN (Eds). The Melanotropic Peptides. Annals of the New York Academy of Sciences 1993; 680: 454-458.

55. Jones EA, Basile AS, Yurdaydin C, Skolnick P. Do benzodiazepine ligands contribute to hepatic encephalopathy? In: Grisolia S, Felipo V (Eds). Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy. New York: Plenum Press, 1994: 57-69.

56. Jones EA, Yurdaydin C, Basile AS. The GABA hypothesis-state of the art. In: Felipo V, Grisolia S (Eds). Cirrhosis, Hyperammonemia and Hepatic Encephalopathy. Advances in Experimental Medicine and Biology 1994; 368: 89-101.

57. Basile AS, Gu Z-Q, Yurdaydin C, Harrison PM, Hughes RD, Pannell L, McKinney A, Jones EA, Williams R. The relationship between benzodiazepine receptor ligand concentrations and the severity of hepatic encephalopathy in humans and an animal model of acute liver failure. In: Capocaccia L, Merli M, Riggio O (Eds). Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, 1995: 193-197.

58. Yurdaydin C, Walsh TJ, Engler H, Basile AS, Jones EA. The role of gut bacteria in the accumulation of benzodiazepine receptor ligands in hepatic encephalopathy. In: Capocaccia L, Merli M, Riggio O (Eds). Advances in Hepatic Encephalopsthy and Metabolic Nitrogen Exchange. Boca Raton. FL: CRC Press, 1995: 198-202.

59. Jones EA, Yurdaydin C, Basile AS. Benzodiazepine antagonists and the management of hepatic encephalopathy. In: Capocaccia L, Merli M, Riggio O (Eds). Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, FL: CRC Press, 1995: 549-563.

60. Yurdaydin C, Swain MG, Vergalla J, Paul SM, Jones EA. Effect of inhibition of ornithine decarboxylase in two animal models of fulminant hepatic failure induced by hepatotoxins. In: Record C, Al-Mardini H (Eds). Advances in Hepatic Encephalopthy and Metabolism in Liver Disease. Ipswich, UK: Ipswich Book Company, 1997: 45- 53.

61. Yurdaydin C, Li Y, Ha J-H, Jones EA, Basile AS. Changes in brain and plasma opioid peptide levels in fulminant hepatic failure: Implications for antagonist therapy. In: Record C, Al-Mardini H (Eds). Advances in Hepatic Encephalopathy and Metabolism in Liver Disease. Ipswich, UK: Ipswich Book Company, 1997: 215-222.

62. Jones EA, Basile AS. The involvement of ammonia with the mechanisms that enhance GABA-ergic neurotransmission in hepatic failure. In: Felipo V, Grisolia S (Eds). Advances in Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy. Advances in Experimental Medicine and Biology 1997; 420: 75-83.

63. Ha J-H, Knauer S, Moody E, Jones EA, Basile AS. Direct enhancement of GABA-ergic neurotransmission by ammonia. In: Felipo V, Grisolia S (Eds). Advances in Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy. Advances in Experimental Medicine and Biology 1997; 420: 85-94.

64. Jones EA, Basile AS. Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure? (1st Hannover International Symposium on Hepatic Encephalopathy). Metabolic Brain Disease 1998; 13: 351-360.

65. Jones EA, Bergasa NV. The pruritus of cholestasis: Evolving pathogenic concepts and therapeutic options. In: Manns MP, Boyer JL, Jansen PLM, Reichen J (Eds). Cholestatic Liver Diseases. Falk Symposium No. 102. Boston: Kluwer Academic, 1998: 248-261.

66. Jones EA, ten Kate FJW, Hoek FJ, Chamuleau RAFM. Mycophenolate mofetil: a potential long-term immunosuppressant treatment for primary biliary cirrhosis. In: Moreno-Otero R, Clemente-Ricote G, Garcia-Monzon C (Eds). Immunology and the Liver: Autoimmunity. Madrid: Aran Ediciones, SA, 2000: 203-207.

67. Giger-Mateeva VI, Jones EA, Reits D, Riemslag FCC, Liberov B, Spekrijse H. Delayed cognitive evoked potentials in cirrhotic patients without overt encephalopathy: The effects of flumazenil. In: Yurdaydin C, Bozkaya H (Eds). Advances in Hepatic Encephalopathy and Metabolism in Liver Disease. Ankara: Turkish Gastroenterology Foundation, 2000: 229-239.

68. Jones EA, Giger-Mateeva VI, Reits D, Riemslag FCC, Liberov B, Spekreijse H. Visual event-related potentials in cirrhotic patients without overt encephalopathy: The effects of flumazenil. (2nd Hannover International Symposium on Hepatic Encephalopathy). Metabolic Brain Disease 2001; 16: 43-53.

69. Jones EA. Potential mechanisms of enhanced GABA-mediated inhibitory neurotransmission in liver failure. In: Albrecht J, Schousboe A (Eds). Glutamine, Glutamate and GABA in the CNS: Transport and Metabolism in Health and Disease. Neurochemistry International 2003; 43: 509-516.

70. Jones EA. Fatigue complicating chronic liver disease. (3rd Hannover International Symposium on Hepatic Encephalopathy). Metabolic Brain Disease 2004; 19: 421-429.

71. Jones EA. Measurement of scratching activity: An objective quantitative efficacy endpoint in trials of therapy for pruritus. (3rd International Workshop for the Study of Itch). Acta Dermato-Venereologica 2005; 85: 473 (abstract).

72. Jones EA. Milestones in research on hepatic encephalopathy. In: Haussinger D, Kircheis G, Schliess F (Eds). Hepatic Encephalopathy and Nitrogen Metabolism. New York: Springer, 2006: 555-572.

73. Haussinger D, Cordoba J, Kircheis G, Vilstrup H, Fleig WE, Jones EA, Schliess F, Blei AT. Definition and assessment of low grade hepatic encephalopathy. In: Haussinger D, Kircheis G, Schliess F (Eds). Hepatic Encephalopathy and Nitrogen Metabolism. New York: Springer, 2006: 423-432.

CORRESPONDENCE

1. Jones EA, Craigie A, Koj A, McFarlane AS. Ammonia nitrogen and protein synthesis. Lancet 1967; ii: 989.

2. Schafer DF, Pappas SC, Jones EA. Studies of experimental hepatic encephalopathy. Gastroenterology 1985; 88: 600-602.

3. Basile AS, Jones EA. The involvement of benzodiazepine receptor ligands in hepatic encephalopathy. Hepatology 1994; 20: 541-542.

4. ter Borg F, Jones EA. Prediction of hepatic inflammatory activity in hepatitis B. Lancet 1998; 352: 1555.

5. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 30: 586-587.

6. Jones EA. Technical medical interventions and the health of populations. Quarterly Journal of Medicine 2004; 97: 309.


BOOK REVIEW

1. Jones EA. Autoimmune Liver Diseases. Second edition. Kravitt EL, Wiesner RN, Nishioka M (Eds). Amsterdam: Elsevier Science, 1998. European Journal of Gastroenterology and Hepatology 1999; 11: 941.
up